Biorestorative Therapies Inc Stock Price, News & Analysis

BioRestorative Therapies (NASDAQ:BRTX) reported Q3 2025 results on Nov 12, 2025, and provided a business update.

Key figures: Q3 revenue $11,800 (royalty only) versus $233,600 in Q3-2024; loss from operations $3.7M; net loss $3.0M, $0.33 per share; cash and marketable securities $4.5M at quarter end plus ~$1.085M gross raised subsequent to quarter end via a registered direct offering.

Corporate and development updates include a registered direct financing (678,125 shares at $1.60) with 508,592 warrants, Fast Track designation and anticipated FDA Type B meeting for BRTX-100, a Japanese Notice of Allowance for the ThermoStem platform, and a new Head of Global Commercial Operations.

BioRestorative Therapies (NASDAQ:BRTX) will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025.

Management will host a conference call at 4:30 p.m. ET the same day to review results and provide a business update. Dial-in numbers are Domestic: 1-888-506-0062, International: 1-973-528-0011 with Access Code: 464585. The call will be broadcast live and archived in the Investors section under News & Events/IR Calendar on the company website.

BioRestorative Therapies (NASDAQ:BRTX) announced that the Japanese Patent Office issued a Notice of Allowance for its ThermoStem® platform on Oct 27, 2025. The allowed claims cover its allogeneic brown adipose-derived stem cell (BADSC) technology and multiple encapsulation and delivery methods, including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolds.

The allowance strengthens IP protection for BioRestorative's cell-based approach as a potential alternative to GLP-1 therapies and supports ongoing licensing and partnership discussions with a commercial-stage regenerative medicine company. The company noted the global obesity market is projected to exceed $100 billion annually by decade-end and cautioned there is no assurance a license or partnership will be completed.

BioRestorative (NASDAQ:BRTX) announced on October 22, 2025 the appointment of Crystal Romano as Head of Global Commercial Operations to lead global commercial operations and innovation for its cell-based product portfolio.

Ms. Romano brings 19 years of leadership in medical aesthetics and regenerative industries and has held roles at Cartessa, Lumenis, Integra LifeSciences, and MiMedx. At Cartessa she helped commercialize 11 new products and a biologics line in less than two years. The company said the hire aims to accelerate commercialization and unlock near-term revenue opportunities across its cell-based platforms.

BioRestorative Therapies (NASDAQ:BRTX) will participate in the 2025 Maxim Growth Summit in New York on October 22–23, 2025. CEO Lance Alstodt and VP of R&D Francisco Silva will join a panel titled “Stem Cell Therapy – A Space That is Ready to have its Day,” moderated by Jason McCarthy, Ph.D., Maxim Group. Management will also hold one-on-one meetings with institutional investors during the event. Due to the event format, no webcast will be available.

BioRestorative Therapies (NASDAQ:BRTX) announced that CEO Lance Alstodt was interviewed on "The Big Biz Show" on October 7, 2025. The interview covered BioRestorative’s recent clinical and regulatory milestones and highlighted commercial opportunities the company is pursuing.

The interview is being or will be broadcast on cable TV and streaming platforms including Roku, and on radio via The Biz Talk Radio Network, Armed Forces Radio, and iHeart Media across 175 countries. Podcasts are available on iHeart Radio, Apple Podcasts, Speaker.com, and TuneIn, and to subscribers of biztv.com and ytaclub.com.

BioRestorative Therapies (NASDAQ: BRTX) entered definitive agreements to sell 678,125 common shares at $1.60 per share in a registered direct offering, compared with a close of $1.50 on Oct 3, 2025. In a concurrent private placement, the company will issue unregistered warrants covering 508,594 shares (75% warrant coverage) with a $2.75 exercise price, exercisable six months after issuance through five years. Gross proceeds are $1.085 million before fees. Closing expected on or about Oct 8, 2025. Net proceeds will fund BRTX-100 clinical trials, ThermoStem preclinical R&D, biocosmeceuticals development, and general corporate purposes.

BioRestorative Therapies (NASDAQ:BRTX) reported its Q2 2025 financial results and business updates. The company achieved revenues of $303,000, marking a 240% increase from Q2 2024, primarily from BioCosmeceutical sales. The quarter ended with a net loss of $2.7 million ($0.30 per share), improved from a $4.0 million loss in Q2 2024.

Key developments include promising preliminary data from the BRTX-100 Phase 2 clinical trial for chronic lumbar disc disease, showing >50% improvement in both ODI and VAS metrics. The company maintains a strong financial position with $7.4 million in cash and investments with no debt. Additionally, BRTX announced a $2 million stock repurchase program through June 2026.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has scheduled its second quarter 2025 financial results announcement for August 12, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the results and provide business updates. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 436077. The call will be available for replay on the company's website.